| Literature DB >> 6763217 |
S Hishon, G Tobin, P J Ciclitira.
Abstract
A small pilot study of levamisole in primary biliary cirrhosis failed to demonstrate any improvement in liver function and immunological abnormalities even in 'early' cases. This may be due to the fact that the defect in the immune system lies in its afferent arm. At present, levamisole, which is potentially toxic, cannot be recommended in conventional doses for the treatment of this disease.Entities:
Mesh:
Substances:
Year: 1982 PMID: 6763217 PMCID: PMC2426569 DOI: 10.1136/pgmj.58.685.701
Source DB: PubMed Journal: Postgrad Med J ISSN: 0032-5473 Impact factor: 2.401